Diuretics Flashcards
Carbonic anhydrase inhibitor:
Acetazolamide
Carbonic anhydrase inhibitor effects (4):
- Weak diuretic
- Na+ excretion (5% filtered load Na+, H2O)
- HCO3- excretion –> metabolic acidosis
- K+ excretion
Carbonic anhydrase inhibitor therapeutic uses (3):
- Decrease intraocular pressure (OA glaucoma)
- Urinary alkalization
- Mountain sickness prophylaxis
Carbonic anhydrase inhibitor adverse effects (4):
- Metabolic acidosis
- Hypokalemia
- Drowsiness
- Hypersensitivity (sulfonamides)
Thiazide MOA:
Inhibition of luminal Na+, Cl- cotransport
- Binds to Cl- binding site
Thiazide site of action:
Distal tubule
Thiazide effects on urine composition (4):
- Na+ and H2O excretion (10% filtered load - modest)
- K+, Cl-, HCO3- excretion
- Decreased Ca2+ excretion
- Decreased uric acid excretion
Thiazide therapeutic uses (5):
- HTN (main use)
- CHF, other edema states
- Hypercalciuric renal stones
- Nephrogenic DI
- Nephrotic syndrome (with spironolactone)
Only thiazide-related drugs effect at lower GFR rates (2):
- Metolazone
- Inadapamide
Thiazide ADRs (7):
- Hypokalemia (digitalis interaction)
- Hypovolemia (rare)
- Hyperglycemia (diabetics)
- Hyperuricemia (gout pts)
- Hypercalcemia
- Hypersensitivity (sulfonamide)
- Hyperlipidemia
Loop diuretic that is NOT a sulfonamide:
Ethacrynic acid
Loop diuretics MOA:
Inhibit Na+, K+, 2Cl- cotransport (at Cl- binding site)
Loop diuretics site of action:
Ascending limb of loop of Henle
Loop diuretic effects (4):
- Na+ and H20 excretion (25%)
- K+, Cl- excretion
- Ca2+ excretion
- +/- HCO3- excretion (higher doses)
Loop diuretic therapeutic uses (4):
- Acute pulmonary edema (IV use)
- Edema (CHF, renal, hepatic)
- HTN (low GFR)
- Hypercalcemia
Loop diuretic ADRs (7):
- Hypovolemia
- Hypokalemia
- Ototoxicity (hearing loss, additive)
- Hyperuricemia
- Hyperglycemia
- Hypersensitivity (Sulfa - not EA)
- Hyperlipidemia
Potassium-sparing diuretics (4):
- Triamterene
- Amiloride
- Spionolactone
- Eplerenone
Aldosterone receptor antagonists (2):
- Spironolactone
- Eplerenone
Aldosterone receptor antagonist MOA:
Competitive antagonist at renal aldosterone receptors
- Decreased Na+/K+ exchange in distal tubule and collecting duct
Aldosterone receptor antagonist effect on urine composition (2):
- Increased Na+, Cl-, H2O excretion (2-3%)
- Decreased K+, H+
Spironolactone therapeutic uses (4):
- Primary hyperaldosteronism
- Prevent hypokalemia with K+ depleting diuretics
- Edema from hepatic cirrhosis and nephrotic syndrome (DoC)
- CHF
Eplerenone therapeutic uses (2):
- HTN
- CHF post-MI
Aldosterone receptor antagonist ADRs (2):
- Hyperkalemia
- Altered hormonal activity
Sodium channel blockers (2):
- Triamterene
- Amiloride